Loading
A phase 3 trial of Garsorasib, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure is a phase 3 interventional study registered as NCT06300177 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 522 participants planned, started 2024-03-28 and due to reach its primary completion in 2026-10. Interventions recorded: D-1553 Tablet, Docetaxel injection. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares KRAS & RAS inhibitors, Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Garsorasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-molecule kinase inhibitors.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, Docetaxel, Cytotoxic chemotherapy.